FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912226299> ?p ?o ?g. }

• W2912226299 endingPage "690" @default.
• W2912226299 startingPage "688" @default.
• W2912226299 abstract "Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle-invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (<pT2) pathologic response rates between split schedule (SS) and conventional schedule (CS) pts, after 1:1 matching on chemotherapy regimen, number of cycles, tumor histology, and clinical stage. Eighty matched pts were identified. pT0 rates were 17.5% (95% confidence interval [CI], 7%-33%) and 32.5% (95% CI, 19%-49%) in SS and CS cisplatin pts, respectively (p = .21), corresponding to an odds ratio for pT0 of 0.45 (95% CI, 0.16-1.31) with SS cisplatin. Split schedule cisplatin was associated with numerically but not statistically significant lower pathologic response rates relative to full dose." @default.
• W2912226299 created "2019-02-21" @default.
• W2912226299 creator A5003720954 @default.
• W2912226299 creator A5004865432 @default.
• W2912226299 creator A5026772513 @default.
• W2912226299 creator A5027428925 @default.
• W2912226299 creator A5027747575 @default.
• W2912226299 creator A5032422193 @default.
• W2912226299 creator A5033372450 @default.
• W2912226299 creator A5035439869 @default.
• W2912226299 creator A5051789976 @default.
• W2912226299 creator A5053181351 @default.
• W2912226299 creator A5055266545 @default.
• W2912226299 creator A5063794457 @default.
• W2912226299 creator A5066635849 @default.
• W2912226299 creator A5071418777 @default.
• W2912226299 creator A5074254953 @default.
• W2912226299 creator A5086466832 @default.
• W2912226299 date "2019-02-06" @default.
• W2912226299 modified "2023-10-12" @default.
• W2912226299 title "Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer" @default.
• W2912226299 cites W1975918912 @default.
• W2912226299 cites W1994196015 @default.
• W2912226299 cites W2051691358 @default.
• W2912226299 cites W254413899 @default.
• W2912226299 cites W2790413325 @default.
• W2912226299 cites W2802899563 @default.
• W2912226299 cites W2890330805 @default.
• W2912226299 cites W2892310850 @default.
• W2912226299 cites W2897581535 @default.
• W2912226299 cites W884353920 @default.
• W2912226299 doi "https://doi.org/10.1634/theoncologist.2018-0561" @default.
• W2912226299 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6516116" @default.
• W2912226299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30728277" @default.
• W2912226299 hasPublicationYear "2019" @default.
• W2912226299 type Work @default.
• W2912226299 sameAs 2912226299 @default.
• W2912226299 citedByCount "14" @default.
• W2912226299 countsByYear W29122262992019 @default.
• W2912226299 countsByYear W29122262992020 @default.
• W2912226299 countsByYear W29122262992021 @default.
• W2912226299 countsByYear W29122262992022 @default.
• W2912226299 countsByYear W29122262992023 @default.
• W2912226299 crossrefType "journal-article" @default.
• W2912226299 hasAuthorship W2912226299A5003720954 @default.
• W2912226299 hasAuthorship W2912226299A5004865432 @default.
• W2912226299 hasAuthorship W2912226299A5026772513 @default.
• W2912226299 hasAuthorship W2912226299A5027428925 @default.
• W2912226299 hasAuthorship W2912226299A5027747575 @default.
• W2912226299 hasAuthorship W2912226299A5032422193 @default.
• W2912226299 hasAuthorship W2912226299A5033372450 @default.
• W2912226299 hasAuthorship W2912226299A5035439869 @default.
• W2912226299 hasAuthorship W2912226299A5051789976 @default.
• W2912226299 hasAuthorship W2912226299A5053181351 @default.
• W2912226299 hasAuthorship W2912226299A5055266545 @default.
• W2912226299 hasAuthorship W2912226299A5063794457 @default.
• W2912226299 hasAuthorship W2912226299A5066635849 @default.
• W2912226299 hasAuthorship W2912226299A5071418777 @default.
• W2912226299 hasAuthorship W2912226299A5074254953 @default.
• W2912226299 hasAuthorship W2912226299A5086466832 @default.
• W2912226299 hasBestOaLocation W29122262991 @default.
• W2912226299 hasConcept C121608353 @default.
• W2912226299 hasConcept C126322002 @default.
• W2912226299 hasConcept C126894567 @default.
• W2912226299 hasConcept C143998085 @default.
• W2912226299 hasConcept C156957248 @default.
• W2912226299 hasConcept C2775910329 @default.
• W2912226299 hasConcept C2776694085 @default.
• W2912226299 hasConcept C2778239845 @default.
• W2912226299 hasConcept C2778292576 @default.
• W2912226299 hasConcept C2780352672 @default.
• W2912226299 hasConcept C2781413609 @default.
• W2912226299 hasConcept C44249647 @default.
• W2912226299 hasConcept C530470458 @default.
• W2912226299 hasConcept C71924100 @default.
• W2912226299 hasConceptScore W2912226299C121608353 @default.
• W2912226299 hasConceptScore W2912226299C126322002 @default.
• W2912226299 hasConceptScore W2912226299C126894567 @default.
• W2912226299 hasConceptScore W2912226299C143998085 @default.
• W2912226299 hasConceptScore W2912226299C156957248 @default.
• W2912226299 hasConceptScore W2912226299C2775910329 @default.
• W2912226299 hasConceptScore W2912226299C2776694085 @default.
• W2912226299 hasConceptScore W2912226299C2778239845 @default.
• W2912226299 hasConceptScore W2912226299C2778292576 @default.
• W2912226299 hasConceptScore W2912226299C2780352672 @default.
• W2912226299 hasConceptScore W2912226299C2781413609 @default.
• W2912226299 hasConceptScore W2912226299C44249647 @default.
• W2912226299 hasConceptScore W2912226299C530470458 @default.
• W2912226299 hasConceptScore W2912226299C71924100 @default.
• W2912226299 hasIssue "5" @default.
• W2912226299 hasLocation W29122262991 @default.
• W2912226299 hasLocation W29122262992 @default.
• W2912226299 hasLocation W29122262993 @default.
• W2912226299 hasLocation W29122262994 @default.
• W2912226299 hasOpenAccess W2912226299 @default.
• W2912226299 hasPrimaryLocation W29122262991 @default.
• W2912226299 hasRelatedWork W2109785281 @default.
• W2912226299 hasRelatedWork W2189722039 @default.

• next